54. J.D. Gómez-Mantilla, I.F. Trocóniz, Z. Parra-Guillén, M.J. Garrido, Review on modeling
anti-antibody responses to monoclonal antibodies. J. Pharmacokinet Pharmacodyn. 41(5),
523–536 (2014)
55. A. Kuriakose, N. Chirmule, P. Nair, Immunogenicity of biotherapeutics: causes and
association with posttranslational modifications. J. Immunol. Res. 2016, 1298473 (2016)
56. H.B. da Silva, R. Fonseca, R.M. Pereira, A. Cassado Ados, J.M. Álvarez, M.R. D’Império
Lima, Splenic macrophage subsets and their function during blood-borne infections. Front
Immunol. 6, 480 (2015)
57. Y.K. Lee, J.M. Jeong, L. Hoigebazar, B.Y. Yang, Y.S. Lee, B.C. Lee et al., Nanoparticles
modified by encapsulation of ligands with a long alkyl chain to affect multispecific and
multimodal imaging. J. Nucl. Med. 53(9), 1462–1470 (2012)
58. H.J. Seo, S.H. Nam, H.J. Im, J.Y. Park, J.Y. Lee, B. Yoo et al., Rapid hepatobiliary excretion
of micelle-encapsulated/radiolabeled upconverting nanoparticles as an integrated form. Sci.
Rep. 5, 15685 (2015)
59. A. Nagao, A.S. Abu Lila, T. Ishida, H. Kiwada, Abrogation of the accelerated blood clearance
phenomenon by SOXL regimen: promise for clinical application. Int. J. Pharm. 441(1–2),
395–401 (2013)
60. J. Wang, S. Iyer, P.J. Fielder, J.D. Davis, R. Deng, Projecting human pharmacokinetics of
monoclonal antibodies from nonclinical data: comparative evaluation of prediction
approaches in early drug development. Biopharm. Drug Dispos. 37(2), 51–65 (2016)
61. A.V. Kamath, Translational pharmacokinetics and pharmacodynamics of monoclonal
antibodies. Drug Discov. Today Technol. 21–22, 75–83 (2016)
62. G. Proetzel, D.C. Roopenian, Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65(1), 148–153 (2014)
63. A.M. Wu, Engineered antibodies for molecular imaging of cancer. Methods 65(1), 139–147
(2014)
64. L.E. Lamberts, S.P. Williams, A.G. Terwisscha van Scheltinga, M.N. Lub-de Hooge, C.
P. Schröder et al., Antibody positron emission tomography imaging in anticancer drug
development. J. Clin. Oncol. 33(13), 1491–1504 (2015)
21 Innate Immunity to Nanomaterials
407
anti-antibody responses to monoclonal antibodies. J. Pharmacokinet Pharmacodyn. 41(5),
523–536 (2014)
55. A. Kuriakose, N. Chirmule, P. Nair, Immunogenicity of biotherapeutics: causes and
association with posttranslational modifications. J. Immunol. Res. 2016, 1298473 (2016)
56. H.B. da Silva, R. Fonseca, R.M. Pereira, A. Cassado Ados, J.M. Álvarez, M.R. D’Império
Lima, Splenic macrophage subsets and their function during blood-borne infections. Front
Immunol. 6, 480 (2015)
57. Y.K. Lee, J.M. Jeong, L. Hoigebazar, B.Y. Yang, Y.S. Lee, B.C. Lee et al., Nanoparticles
modified by encapsulation of ligands with a long alkyl chain to affect multispecific and
multimodal imaging. J. Nucl. Med. 53(9), 1462–1470 (2012)
58. H.J. Seo, S.H. Nam, H.J. Im, J.Y. Park, J.Y. Lee, B. Yoo et al., Rapid hepatobiliary excretion
of micelle-encapsulated/radiolabeled upconverting nanoparticles as an integrated form. Sci.
Rep. 5, 15685 (2015)
59. A. Nagao, A.S. Abu Lila, T. Ishida, H. Kiwada, Abrogation of the accelerated blood clearance
phenomenon by SOXL regimen: promise for clinical application. Int. J. Pharm. 441(1–2),
395–401 (2013)
60. J. Wang, S. Iyer, P.J. Fielder, J.D. Davis, R. Deng, Projecting human pharmacokinetics of
monoclonal antibodies from nonclinical data: comparative evaluation of prediction
approaches in early drug development. Biopharm. Drug Dispos. 37(2), 51–65 (2016)
61. A.V. Kamath, Translational pharmacokinetics and pharmacodynamics of monoclonal
antibodies. Drug Discov. Today Technol. 21–22, 75–83 (2016)
62. G. Proetzel, D.C. Roopenian, Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65(1), 148–153 (2014)
63. A.M. Wu, Engineered antibodies for molecular imaging of cancer. Methods 65(1), 139–147
(2014)
64. L.E. Lamberts, S.P. Williams, A.G. Terwisscha van Scheltinga, M.N. Lub-de Hooge, C.
P. Schröder et al., Antibody positron emission tomography imaging in anticancer drug
development. J. Clin. Oncol. 33(13), 1491–1504 (2015)
21 Innate Immunity to Nanomaterials
407